213 related articles for article (PubMed ID: 22079605)
21. A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection.
Cover J; Namagembe A; Tumusiime J; Lim J; Drake JK; Mbonye AK
Contraception; 2017 Mar; 95(3):306-311. PubMed ID: 27789309
[TBL] [Abstract][Full Text] [Related]
22. Initiation and continuation rates seen in 2-year experience with Same Day injections of DMPA.
Nelson AL; Katz T
Contraception; 2007 Feb; 75(2):84-7. PubMed ID: 17241834
[TBL] [Abstract][Full Text] [Related]
23. Contraceptive efficacy and safety of DMPA-SC.
Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM
Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329
[TBL] [Abstract][Full Text] [Related]
24. Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi.
Burke HM; Packer C; Buluzi M; Healy E; Ngwira B
Contraception; 2018 Nov; 98(5):405-410. PubMed ID: 29706227
[TBL] [Abstract][Full Text] [Related]
25. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
Keder LM; Rulin MC; Gruss J
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
[TBL] [Abstract][Full Text] [Related]
26. Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial.
Dempsey A; Roca C; Westhoff C
Contraception; 2010 Sep; 82(3):250-5. PubMed ID: 20705153
[TBL] [Abstract][Full Text] [Related]
27. Patient satisfaction of depot medroxyprogesterone acetate (dmpa-sc) injection as contraceptive.
Chaudhri R; Rizvi F; Afzal M
J Pak Med Assoc; 2010 Jul; 60(7):536-40. PubMed ID: 20578601
[TBL] [Abstract][Full Text] [Related]
28. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
[TBL] [Abstract][Full Text] [Related]
29. Depot-medroxyprogesterone acetate contraception use among Salvadoran women: an in-depth analysis of attitudes and experiences.
Cremer M; Ditzian L; April A; Peralta E; Klausner D; Podolsky R; Dierking E
J Womens Health (Larchmt); 2011 Nov; 20(11):1751-6. PubMed ID: 21823919
[TBL] [Abstract][Full Text] [Related]
30. A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate.
Wernick HJ; Wentzel E; Jackson K; Schmuhl K; Valenti O; Bonny AE; Berlan ED
J Pediatr Adolesc Gynecol; 2023 Dec; 36(6):549-552. PubMed ID: 37354986
[TBL] [Abstract][Full Text] [Related]
31. Depo Now: preventing unintended pregnancies among adolescents and young adults.
Rickert VI; Tiezzi L; Lipshutz J; León J; Vaughan RD; Westhoff C
J Adolesc Health; 2007 Jan; 40(1):22-8. PubMed ID: 17185202
[TBL] [Abstract][Full Text] [Related]
32. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.
MacLachlan E; Atuyambe LM; Millogo T; Guiella G; Yaro S; Kasasa S; Bukenya J; Nyabigambo A; Mubiru F; Tumusiime J; Onadja Y; Zan LM; Goeum/Sanon C; Kouanda S; Namagembe A
Contraception; 2018 Nov; 98(5):423-429. PubMed ID: 30125558
[TBL] [Abstract][Full Text] [Related]
33. Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.
Cover J; Ba M; Drake JK; NDiaye MD
Contraception; 2019 Feb; 99(2):137-141. PubMed ID: 30439358
[TBL] [Abstract][Full Text] [Related]
34. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life changes among users of depot medroxyprogesterone acetate for contraception.
Wanyonyi SZ; Stones WR; Sequeira E
Contraception; 2011 Nov; 84(5):e17-22. PubMed ID: 22018133
[TBL] [Abstract][Full Text] [Related]
36. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
Dragoman MV; Gaffield ME
Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of injectable contraceptive users in a low-income population in Texas.
Sangi-Haghpeykar H; Poindexter AN; Moseley DC; Bateman L; Reid ED
Fam Plann Perspect; 1995; 27(5):208-11, 225. PubMed ID: 9104608
[TBL] [Abstract][Full Text] [Related]
38. An observational study to test the acceptability and feasibility of using medical and nursing students to instruct clients in DMPA-SC self-injection at the community level in Kinshasa.
Bertrand JT; Bidashimwa D; Makani PB; Hernandez JH; Akilimali P; Binanga A
Contraception; 2018 Nov; 98(5):411-417. PubMed ID: 30120925
[TBL] [Abstract][Full Text] [Related]
39. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
Liu J; Shen J; Diamond-Smith N
Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
[TBL] [Abstract][Full Text] [Related]
40. Body weight and body composition of depot medroxyprogesterone acetate users.
Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
